Summary
| Diagnosis | Sex | Age | Nationality |
|---|---|---|---|
| Cerebral Palsy | Male | 3 years | Latvia |
| Injections | Cell type | Admission date | Discharge date |
|---|---|---|---|
| 8 | UCMSC | February 23rd 2022 | March 17th 2022 |
Medical history
The patient was diagnosed with cerebral palsy (tetraperesis) following herpes meningoencephalitis. MRI scans revealed severe brain damage on the right side and minor damage on the left. Currently six months old, he exhibits relatively normal development, albeit with weaker left arm movement and slower mobility compared to peers. Physiotherapies and massages, along with home exercises, constitute his treatment regimen. Medications include phenobarbital, acyclovir for herpes, and depakine syrup to prevent seizures, as per EEG recommendations. His mother’s herpes infection during pregnancy and subsequent outbreak during childbirth were noted as relevant medical history.
Condition On Admission
The patient demonstrates limited speech and slower motor skills, though he can roll over, hold his head up, and grasp objects with his right arm. There have been no reported allergies, abnormal bowel movements, or other significant gastrointestinal issues. Despite the herpes infection history, no communicable illnesses are present. Notably, there’s no epilepsy/seizures recorded thus far. With no major surgeries, bedsores, ulcers, or respiratory complications, the patient’s current condition primarily centers around managing cerebral palsy and monitoring his developmental progress.
Treatment Schedule
Patient received 8 packs of umbilical cord derived stem cell (UCMSC) by intravenous (IV) injection and intrathecal injection via lumbar puncture (LP), as per the schedule below:
| Number | Date | Cell Type | Delivery Method | Side Effects |
|---|---|---|---|---|
| 1 | 2023-03-07 | UCMSC | Intrathecal Injection & Intravenous Injection | none reported |
| 2 | 2023-03-10 | UCMSC | Intrathecal Injection & Intravenous Injection | none reported |
| 3 | 2023-03-14 | UCMSC | Intrathecal Injection & Intravenous Injection | none reported |
| 4 | 2023-03-17 | UCMSC | Intrathecal Injection | none reported |
| 5 | 2023-03-12 | UCMSC | Intrathecal Injection | none reported |
Condition 12 months after treatment
The patient’s progress post-treatment shows notable improvements in several areas, particularly in speech development and motor skills. Despite initial concerns, the patient has demonstrated progress in verbal communication, attempting two to three-word sentences and actively engaging in speech repetition. Additionally, advancements in physical activities such as puzzle-solving, Lego play, and learning to use bicycle pedals reflect improvements in motor coordination. The patient’s participation in kindergarten with specialized attention and therapy sessions further supports his developmental progress.
| Symptom | Parents’ Assessment of Improvement |
|---|---|
| Balance | Small improvement |
| Learning disability | Small improvement |
| Mood disorder | Small improvement |
| Standing up | Small improvement |
| Language functions | Mostly able to do |
| Own actions | Able to do |
| Physical functions | Able to do |
| Recognize functions | Mostly able to do |
| Social adaptability | Mostly able to do |
